Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF

OBJECTIVES: COMMANDER-HF was a randomised trial comparing rivaroxaban 2.5 mg two times a day to placebo, in addition to antiplatelet therapy, in patients hospitalised for worsening heart failure with coronary artery disease and sinus rhythm. Patients with diabetes are at increased risk of cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Abhinav, Caldeira, Daniel, Razaghizad, Amir, Pinto, Fausto J, van Veldhuisen, Dirk J, Mehra, Mandeep R, Lam, Carolyn S P, Cleland, John, Anker, Stefan D, Greenberg, Barry, Ferreira, Joao Pedro, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423780/
https://www.ncbi.nlm.nih.gov/pubmed/37567750
http://dx.doi.org/10.1136/bmjopen-2022-068865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423780/
https://www.ncbi.nlm.nih.gov/pubmed/37567750
http://dx.doi.org/10.1136/bmjopen-2022-068865

Ejemplares similares